Our ongoing commitment.

Produce Humacyte’s life-sustaining, human, bioengineered HAV designed to become the patient’s own and integrate naturally for patients who need a better clinical alternative for vascular access.

What matters to us.

We are committed to becoming the leader in novel, human acellular matrix products for vascular and non-vascular applications. These products are engineered to be immediately available and can have the potential to improve efficacy, safety, and treatment outcomes in patients with a broad range of disease conditions.

Our goal is to develop and commercialize our products in the U.S., and potentially license commercialization rights in ex-U.S. markets. Our corresponding product development strategy aims for the fastest speed to market by pursuing approval for indications with the greatest chance of clinical success and safety, through well-established regulatory pathways for approval.

Humacyte is a privately-held company that was founded in 2004 by Laura Niklason, MD. PhD., a world leader in tissue engineering, and currently Professor of Biomedical Engineering and Anesthesia at Yale University.

Dr. Niklason co-founded Humacyte along with Drs. Shannon Dahl and Juliana Blum. Humacyte’s research platforms and core technologies are based on the research conducted by Drs. Niklason and Dahl at Duke University, and by Dr. Niklason at the Massachusetts Institute of Technology in the laboratory of Dr. Robert Langer.

Our team of senior management advisors and board of directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance, and intellectual property management.

See how far we've come.

We’re proud of the steps we’ve taken and the progress we’ve made.  

March 27th, 2019

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”

The medical journal, Science Translational Medicine, published work demonstrating Humacyte’s human acellular vessels (HAVs) repopulate with the patient’s own cells to form a living vascular tissue. The results suggest that the HAV may be an innovative advancement as a bioengineered vessel that develops characteristics of a living tissue over time.

Industry Visionaries and Healthcare Executives

Our leadership team is focused on developing a novel platform technology to shape human tissues to be used for hemodialysis and the treatment of vascular diseases.


Jeffrey H. Lawson, MD, PhD

President and Chief Executive Officer

Douglas L. Blankenship

Chief Financial Officer

Laura E. Niklason, MD, PhD

Founder & Executive Clinical Director

Heather Prichard, PhD

Chief Operating Officer

Juliana L. Blum, PhD

Executive Vice President, Strategic Business Operations and Co-Founder

William Tente, MS

Chief Regulatory Officer

Jack Harvey

Vice President of Commercial Bioprocessing

Sabrina Osborne

Executive Vice President, Business Strategy & People

Scott Weit, PHD

Vice President of Quality

Board of Directors

Carrie S. Cox

Carrie S. Cox is Executive Chairman of Humacyte, Inc. Ms. Cox joined Humacyte in 2010 and served as Chairman and CEO until January 2018, where she led the company through significant business, clinical, regulatory and operational milestones. Prior to Humacyte, she most recently served as Chairman of Prism Pharmaceuticals, sold to Baxter Corporation in 2011. Ms. Cox was also EVP and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. She was responsible for the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a five-year CAGR of 22%. Prior to that, Ms. Cox held a similar role as President, Global Prescription Business at Pharmacia Corporation.

Previously, Ms. Cox served as SVP of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and as VP of Women’s Healthcare at Wyeth-Ayerst. She spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility. Ms. Cox currently serves as Chairman of electroCore, Inc.’s Board of Directors, and is on the Boards of Directors of Texas Instruments, Cardinal Health, and Celgene, and she has served as Lead Director for Texas Instruments. Ms. Cox has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and she was named to “Top 10 Women in Biotech” by Fierce Biotech publications in 2012. Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. Ms. Cox received her B.S. from Massachusetts College of Pharmacy, and worked for several years in retail and hospital pharmacy

Robert Anderson, M.D.

Cardiac Surgeon, former Chief of Surgery at Duke University, and a Key Opinion leader in cardiovascular surgery.

Brady W. Dougan

Former CEO of Credit-Suisse.

Robert Langer, Sc.D.

David Koch Institute Professor at Massachusetts Institute of Technology, and a world leader in tissue engineering and regenerative Medicine.

Laura Niklason, M.D., Ph.D.

Humacyte Founder, Nicholas Greene Professor of Anesthesiology and Professor of Biomedical Engineering, Vice-Chair for Anesthesia at Yale, and world leader in cellular therapies and regenerative medicine.

Dale A. Sander

Senior Vice President, Global Accounting Officer at Sutherland Global Services, Inc., Former Chief Financial Officer role at Biolex Therapeutics and leadership positions at life science companies Maxim Pharmaceuticals, Inc., Xytronyx, Inc., and Tactyl Technologies, Inc.

Honorable Kathleen Sebelius

Former 21st Secretary of the Department of Health and Human Services (HHS). Former Governor of Kansas, she served two terms as the Kansas insurance commissioner, and four terms in the Kansas Legislature.

Max Wallace, J.D.

Former CEO of Cogent Neurosciences, former CEO of Trimeris, and currently heads Accelerate Brain Cancer Cure, a private foundation.

Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products.

Our new state-of-the–art cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility will also be home to our R&D and administration capabilities.

We’re building strong relationships with our growing family of partners.

We’re proud of our partners and honored that they stand with us on our commitment to lifesaving possibilities.


We’d love to hear from you.

Scroll to Top